BRIEF—AbbVie gains Venclexta approval in Canada

Chicago’s AbbVie has received approval in Canada for Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia (CLL), in combination with rituximab.

The approval was based on data which show a significant improvement in progression-free survival, reducing the risk of disease progression or death by 81% compared with standard of care.

Approximately 2,400 cases of CLL are diagnosed every year in Canada.